Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy
GJ Besson, D McMahon, F Maldarelli… - Clinical infectious …, 2012 - academic.oup.com
GJ Besson, D McMahon, F Maldarelli, JW Mellors
Clinical infectious diseases, 2012•academic.oup.comRNA suppression, and sample size may be responsible for the discrepancies between the 2
studies. Nevertheless, most evidence reported to date, including the results presented here,
refute ongoing HIV-1 replication in patients receiving effective antiretroviral therapy as the
source of residual viremia [2, 5, 6]. Additional studies are needed, however, to assess the
impact of treatment intensification on HIV-1 replication in tissue compartments.
studies. Nevertheless, most evidence reported to date, including the results presented here,
refute ongoing HIV-1 replication in patients receiving effective antiretroviral therapy as the
source of residual viremia [2, 5, 6]. Additional studies are needed, however, to assess the
impact of treatment intensification on HIV-1 replication in tissue compartments.
RNA suppression, and sample size may be responsible for the discrepancies between the 2 studies. Nevertheless, most evidence reported to date, including the results presented here, refute ongoing HIV-1 replication in patients receiving effective antiretroviral therapy as the source of residual viremia [2, 5, 6]. Additional studies are needed, however, to assess the impact of treatment intensification on HIV-1 replication in tissue compartments.
Oxford University Press